Cover Image
Market Research Report
Product code 
1031674

Breast Cancer Diagnostics Market Research Report by Type, by Technique, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

Published: | 360iResearch LLP | 198 Pages | Delivery time: 1-2 business days

Price

Back to Top
Breast Cancer Diagnostics Market Research Report by Type, by Technique, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
Published: October 5, 2021
360iResearch LLP
Content info: 198 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Global Breast Cancer Diagnostics Market size was estimated at USD 5,286.71 million in 2020 and expected to reach USD 5,685.81 million in 2021, at a CAGR 7.88% to reach USD 8,337.08 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Breast Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Biopsy, Blood Tests, Genomic Tests, and Imaging.

Based on Technique, the market was studied across Imaging, Molecular Testing, and Tissue Biopsy Tests. The Imaging is further studied across Analog Mammography, Breast Ultrasound System, Digital Mammography, Mammography, MRI Scan, and PET/CT Scan.

Based on End-user, the market was studied across Diagnostic Laboratories, Hospitals & Ambulatory Surgery Center, and Research & Academic Institutes.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Diagnostics Market, including Abbott Laboratories, Agilent Technologies, Inc., Ascenda BioSciences LLC, AstraZeneca, PLC, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., BioNTech SE, C.R. Bard, Inc., Danaher Corporation, Epigenomics Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, GE Healthcare, Genomic Health, Hologic Inc., Illumina, Inc., Koninklijke Philips N.V., Leica Biosystems, Myriad Genetics, Inc., NanoString Technologies, Inc, Paragon Biosciences LLC, Questex LLC, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Todos Medical, and Toshiba Corporation.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Breast Cancer Diagnostics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Diagnostics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Diagnostics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Breast Cancer Diagnostics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Diagnostics Market?
  • 6. What is the market share of the leading vendors in the Global Breast Cancer Diagnostics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Breast Cancer Diagnostics Market?
Product Code: MRR-A26E0E57406E

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Dynamics

  • 5.1. Introduction
  • 5.2. Drivers
    • 5.2.1. Increasing incidence of breast cancer
    • 5.2.2. Favourable reimbursement framework for breast cancer diagnosis
    • 5.2.3. Growing number of breast cancer screening programs
  • 5.3. Restraints
    • 5.3.1. Dearth of the skilled and trained professionals
  • 5.4. Opportunities
    • 5.4.1. Technological advancements such as introduction of hybrid imaging technique
    • 5.4.2. Focus on development of effective diagnostic
  • 5.5. Challenges
    • 5.5.1. Ignorance of the prediagnostic symptoms

6. Breast Cancer Diagnostics Market, by Type

  • 6.1. Introduction
  • 6.2. Biopsy
  • 6.3. Blood Tests
  • 6.4. Genomic Tests
  • 6.5. Imaging

7. Breast Cancer Diagnostics Market, by Technique

  • 7.1. Introduction
  • 7.2. Imaging
    • 7.2.1. Analog Mammography
    • 7.2.2. Breast Ultrasound System
    • 7.2.3. Digital Mammography
    • 7.2.4. Mammography
    • 7.2.5. MRI Scan
    • 7.2.6. PET/CT Scan
  • 7.3. Molecular Testing
  • 7.4. Tissue Biopsy Tests

8. Breast Cancer Diagnostics Market, by End-user

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals & Ambulatory Surgery Center
  • 8.4. Research & Academic Institutes

9. Americas Breast Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Breast Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand

11. Europe, Middle East & Africa Breast Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Key Player
  • 12.4. Competitive Scenario
    • 12.4.1. Merger & Acquisition
    • 12.4.2. Agreement, Collaboration, & Partnership
    • 12.4.3. New Product Launch & Enhancement
    • 12.4.4. Investment & Funding
    • 12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Abbott Laboratories
  • 13.2. Agilent Technologies, Inc.
  • 13.3. Ascenda BioSciences LLC
  • 13.4. AstraZeneca, PLC
  • 13.5. Becton, Dickinson, and Company
  • 13.6. Bio-Rad Laboratories, Inc
  • 13.7. Biocept, Inc.
  • 13.8. BioNTech SE
  • 13.9. C.R. Bard, Inc.
  • 13.10. Danaher Corporation
  • 13.11. Epigenomics Inc
  • 13.12. F. Hoffmann-La Roche Ltd
  • 13.13. FUJIFILM Holdings Corporation
  • 13.14. GE Healthcare
  • 13.15. Genomic Health
  • 13.16. Hologic Inc.
  • 13.17. Illumina, Inc.
  • 13.18. Koninklijke Philips N.V.
  • 13.19. Leica Biosystems
  • 13.20. Myriad Genetics, Inc.
  • 13.21. NanoString Technologies, Inc
  • 13.22. Paragon Biosciences LLC
  • 13.23. Questex LLC
  • 13.24. Siemens Healthineers AG
  • 13.25. Thermo Fisher Scientific Inc.
  • 13.26. Todos Medical
  • 13.27. Toshiba Corporation

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: MARKET DYNAMICS
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2026
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2026 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, 2018-2026 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC TESTS, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC TESTS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2020 VS 2026 (%)
  • FIGURE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2026
  • FIGURE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, 2018-2026 (USD MILLION)
  • FIGURE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, 2018-2026 (USD MILLION)
  • FIGURE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, 2018-2026 (USD MILLION)
  • FIGURE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, 2018-2026 (USD MILLION)
  • FIGURE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2020 VS 2026 (%)
  • FIGURE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2020 VS 2026 (USD MILLION)
  • FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2026
  • FIGURE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2026 (USD MILLION)
  • FIGURE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 41. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, 2018-2026 (USD MILLION)
  • FIGURE 42. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 43. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2026 (USD MILLION)
  • FIGURE 44. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 45. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 46. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 47. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 48. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 49. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 50. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 51. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 52. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 53. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 54. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 55. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 56. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 57. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 58. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 59. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 60. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 61. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 62. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 63. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 64. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 65. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 66. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 67. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 68. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 69. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 70. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 71. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 72. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 73. UNITED ARAB EMIRATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 74. UNITED KINGDOM BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 75. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 76. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 77. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2026 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC TESTS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2026 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 23. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 24. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 25. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 26. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 27. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 28. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 30. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 31. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 32. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 33. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 34. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 35. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 36. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 37. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 38. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 39. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 40. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 41. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 42. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 43. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 44. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 45. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 46. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 47. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 48. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 49. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 50. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 51. UNITED ARAB EMIRATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 52. UNITED KINGDOM BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: SCORES
  • TABLE 54. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BUSINESS STRATEGY
  • TABLE 55. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: PRODUCT SATISFACTION
  • TABLE 56. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: RANKING
  • TABLE 57. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 58. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: MERGER & ACQUISITION
  • TABLE 59. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 60. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 61. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: INVESTMENT & FUNDING
  • TABLE 62. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 63. GLOBAL BREAST CANCER DIAGNOSTICS MARKET: LICENSE & PRICING